At September 30, 2022, cash and cash equivalents were $174.7 million, with no debt. "The clinical development of oral simufilam for Alzheimer’s disease continues to make headway," said Remi Barbier, President & CEO. "We now have over 650 patients enrolled in our on-going Phase 3 studies of simufilam in Alzheimer’s disease, up from 150 patients approximately six months ago. We also look forward to presenting new clinical data for simufilam from two other ongoing studies in Alzheimer’s disease."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SAVA:
- Cassava Sciences Files Lawsuit Against Perpetrators of “Short and Distort” Campaign
- Cassava Sciences Announces Expansion of Leadership Team
- Cassava Sciences appoints Cook as SVP, general counsel
- Cassava Sciences Announces Initiation of an Open-label Extension Study
- Short Report: Asana bearish position builds again after last-month’s squeeze
